Evogene Ltd
NASDAQ:EVGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Evogene Ltd
Cash & Cash Equivalents
Evogene Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Evogene Ltd
NASDAQ:EVGN
|
Cash & Cash Equivalents
$13m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
2%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash & Cash Equivalents
$75.5m
|
CAGR 3-Years
30%
|
CAGR 5-Years
1%
|
CAGR 10-Years
31%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Cash & Cash Equivalents
$1.9m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-13%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash & Cash Equivalents
$110.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash & Cash Equivalents
$7.1m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Cash & Cash Equivalents
$4.7m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-1%
|
|
Evogene Ltd
Glance View
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
See Also
What is Evogene Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
13m
USD
Based on the financial report for Dec 31, 2025, Evogene Ltd's Cash & Cash Equivalents amounts to 13m USD.
What is Evogene Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
2%
Over the last year, the Cash & Cash Equivalents growth was -15%. The average annual Cash & Cash Equivalents growth rates for Evogene Ltd have been -24% over the past three years , -22% over the past five years , and 2% over the past ten years .
